

IFW 1614

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Beswick et al.

Docket No.

PG4893USW

Application No.

10/527,799

Filing Date

8/17/05

Examiner


Customer No.

23347

Group Art Unit

1614

Invention: **COX-2 Inhibiting Pyridine Derivatives**



I hereby certify that this Supplemental IDS w/references

(Identify type of correspondence)

is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope

addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

November 16, 2005

(Date)

Valerie L. Phillips

(Typed or Printed Name of Person Mailing Correspondence)

Valerie L. Phillips

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



IA PG4893USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Beswick et al.

Serial No.: 10,527,799

Group Art Unit: 1614

File Date: August 17, 2005

Examiner:

For: COX-2 Inhibiting Pyrimidine Derivatives

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: References 8-39
☐ Copies of the references were submitted in parent application _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ **The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action or after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).**

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.


☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



J. Scott Young
Registration No. 45,582

Date:
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8160
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT <div style="text-align: center; margin-top: 20px;">  </div>				SERIAL NO.		10/527,799	
				FILING DATE		August 17, 2005	
				APPLICANT		Beswick et al.	
				GROUP		1614	
				EXAMINER			
				ATTORNEY DOCKET NO.		PG4893USW	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1	2003/0018023	Jan. 23, 2003	Pinto et al.			
	2	5,849,758	Dec. 15, 1998	Kleemann et al.			
	3	5,972,842	Oct. 26, 1999	Maier et al.			
	4	5,985,886	Nov. 16, 1999	Elliott et al.			
	5	6,121,202	Sept. 19, 2000	Karp et al.			
	6	6,248,892	June 19, 2001	Noerenberg et al.			
	7	6,355,799	Mar. 12, 2002	Gupta et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	8	CA 2169231	Aug. 16, 1996	CANADA			
	9	DE 19651099	June 10, 1998	GERMANY			
	10	DE 19708928	Sept. 10, 1998	GERMANY			
	11	DE 19831246	Jan. 1, 2000	GERMANY			
	12	EP 0723960	July 31, 1996	EUROPE			
	13	EP 0820996	Jan. 28, 1998	EUROPE			
	14	JP 09241161	Sept. 16, 1997	JAPAN			
	15	JP 2000026421	Jan. 25, 2000	JAPAN			
	16	JP 2001081074	Mar. 27, 2001	JAPAN			
	17	JP 2001252044	Nov. 22, 1999	JAPAN			
	18	WO 94/24110	Oct. 27, 1994	WIPO			X Abstract
	19	WO 97/37989	Oct. 16, 1997	WIPO			
	20	WO 97/38996	Oct. 23, 1997	WIPO			
	21	WO 99/21837	May 6, 1999	WIPO			
	22	WO 99/42455	Aug. 26, 1999	WIPO			
	23	WO 99/55668	April 11, 1999	WIPO			X Abstract
	24	WO 99/55675	Nov. 4, 1999	WIPO			
	25	WO 99/64412	Dec. 16, 1999	WIPO			
	26	WO 00/47553A2	Aug. 17, 2000	WIPO			
	27	WO 01/38295	May 31, 2001	WIPO			X Abstract
	28	WO 01/45703	June 28, 2001	WIPO			
	29	WO 01/62233	Aug. 30, 2001	WIPO			
	30	WO 02/00647	Jan. 3, 2002	WIPO			
	31	WO 02/00655	Jan. 3, 2002	WIPO			
	32	WO 02/07721	Jan. 31, 2002	WIPO			
Continue on page <u>2</u>							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
Continue on page _____							
EXAMINER						DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/527,799	
				FILING DATE		August 17, 2005	
				APPLICANT		Beswick et al.	
				GROUP		1614	
				EXAMINER			
				ATTORNEY DOCKET NO.		PG4893USW	

U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page _____

FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	33	WO 02/44137	June 6, 2002	WIPO			X Abstract
	34	WO 02/55484	July 18, 2002	WIPO			X Abstract
	35	WO 02/59122	Aug. 1, 2002	WIPO			
	36	WO 02/100838	Dec. 19, 2002	WIPO			
	37	WO 03/004472	Jan. 16, 2003	WIPO			
	38	WO 03/014092	Feb. 20, 2003	WIPO			
	39	WO 03/022219	Mar. 20, 2003	WIPO			

Continue on page _____

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)		

Continue on page _____

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.